悦康药业：子公司注射用YKYY031获得国家药品监督管理局临床试验批准

Core Viewpoint - The announcement indicates that Yuyuan Pharmaceutical's wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injectable YKYY031, a generic mRNA tumor vaccine intended for the treatment of advanced solid tumors [1] Group 1 - Yuyuan Pharmaceutical's subsidiary has obtained a clinical trial approval notice for YKYY031 [1] - YKYY031 is designed as a generic mRNA tumor vaccine [1] - The vaccine is aimed at treating advanced solid tumors [1]